Virag R, Shoukry K, Floresco J, Nollet F, Greco E
Centre d'Etudes et de Recherches de l'Impuissance, Paris, France.
J Urol. 1991 Feb;145(2):287-92; discussion 292-3. doi: 10.1016/s0022-5347(17)38316-7.
Of 615 patients with impotence of varying etiologies who were followed from 12 to 96 months after the institution of intracavernous self-injection therapy with vasoactive drugs (papaverine alone, papaverine and alpha-blockers, and Ceritine, a new multilevel acting drug) 87% (533 patients) returned for followup visits or were regularly contacted. Of these patients sexual activity was restored in 91%. The dropout rate was 11.25%. The 114 episodes of prolonged erections among 51 patients (4.57%) represented less than 3 per 1,000 of the 34,875 recorded injections. All patients were treated without complications. The percentage of patients suffering from nodules or permanent deformations was 2.8%. There were no cases of intracavernous fibrosis. The percentage of satisfied patients (satisfaction index 7 or greater) was 84.8%. Improvement in spontaneous erections during sexual intercourse was obtained in 65% of the cases: 15% no longer needed self-injections and 50% only used them occasionally while 35% remained entirely dependent.
615例病因各异的阳痿患者在采用血管活性药物（单独使用罂粟碱、罂粟碱与α受体阻滞剂以及新型多级作用药物西力士）进行海绵体内自我注射治疗后的12至96个月内接受随访，其中87%（533例患者）前来复诊或保持定期联系。在这些患者中，91%恢复了性活动。失访率为11.25%。51例患者（4.57%）出现114次持续性勃起，在记录的34,875次注射中，发生率低于千分之三。所有患者治疗过程均无并发症。出现硬结或永久性畸形的患者比例为2.8%。未发生海绵体内纤维化病例。满意患者（满意度指数为7或更高）的比例为84.8%。65%的患者在性交时自发性勃起得到改善：15%不再需要自我注射，50%仅偶尔使用，35%仍完全依赖自我注射。
